Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM)

被引：0
|
作者：
Wang, M.
Bensinger, W.
Martin, T.
Alsina, M.
Siegel, D. S. D.
Gabrail, N. Y.
Hari, P.
Singhal, S.
Vescio, R. A.
Assouline, S. E.
Kunkel, L. A.
Vallone, M.
Wong, A.
Niesvizky, R.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[5] John Theurer Canc Ctr, Hackensack, NJ USA
[6] Gabrail Canc Ctr, Canton, OH USA
[7] Med Coll Wisconsin, Miwaukee, WI USA
[8] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA
[9] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[10] McGill Univ, Jewish Gen Hosp, Clin Res Unit, Segal Canc Ctr,Lady Davis Inst, Montreal, PQ H3T 1E2, Canada
[11] ACT Biotech Inc, San Francisco, CA USA
[12] Onyx Pharmaceut, San Francisco, CA USA
[13] Onyx Pharmaceut, Emeryville, CA USA
[14] Cornell Univ, New York Presbyterian Hosp, Ctr Excellence Lymphoma & Myeloma, Weill Med Coll, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.8025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8025
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study
    Pozzi, Samantha
    Gentile, Massimo
    Sacchi, Stefano
    Marcheselli, Raffaella
    Corso, Alessandro
    Cocito, Federica
    Musto, Pellegrino
    Guarini, Attilio
    Minoia, Carla
    Vincelli, Iolanda
    Ria, Roberto
    Rivolti, Elena
    Mele, Giuseppe
    Bari, Alessia
    Mazzone, Carla
    Badiali, Stefania
    Marcheselli, Luigi
    Palumbo, Antonio
    Morabito, Fortunato
    LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 552 - 559
  • [32] Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) plus daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.
    Siegel, David Samuel DiCapua
    Schiller, Gary J.
    Samaras, Christy Joy
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin W.
    Seet, Christopher
    Talamo, Giampaolo
    Srinivas, Shanthi
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand Marquess
    Fonseca, Gustavo
    Reece, Donna Ellen
    Zafar, Faiza
    Chung, Weiyuan
    Bahlis, Nizar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Jian Hou
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Dao-bin Zhou
    Li Yu
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Huisheng Ai
    Jingshan Zhang
    Honeylet Wortman-Vayn
    Nianhang Chen
    Jay Mei
    Jianmin Wang
    Journal of Hematology & Oncology, 6
  • [34] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Hou, Jian
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Zhou, Dao-bin
    Yu, Li
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    Wortman-Vayn, Honeylet
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [35] Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study
    Mateos, Maria-Victoria
    Orlowski, Robert Z.
    Ocio, Enrique M.
    Rodriguez-Otero, Paula
    Reece, Donna
    Moreau, Philippe
    Munshi, Nikhil
    Avigan, David E.
    Siegel, David S.
    Ghori, Razi
    Farooqui, Mohammed Z. H.
    Marinello, Patricia
    San-Miguel, Jesus
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (05) : E117 - E121
  • [36] Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)
    Samuel, David
    Martin, Thomas
    Wang, Michael
    Vij, Ravi
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Lonial, Sagar
    Kukreti, Vishal
    Bahlis, Nizar J.
    Alsina, Melissa
    Chanan-Khan, Asher A.
    Somlo, George
    Buadi, Francis
    Reu, Frederic J.
    Zonder, Jeffrey A.
    Song, Kevin
    Stadtmauer, Edward
    Wong, Alvin F.
    Vallone, Marcy
    Chang, Yu-Lin
    Kauffman, Michael
    Orlowski, Robert Z.
    Stewart, A. Keith
    Singhal, Seema B.
    BLOOD, 2010, 116 (21) : 433 - 433
  • [37] Phase II study of pegylated liposomal doxorubicin (PLD), low-dose dexamethasone (DEX), and lenalidomide (LEN) in patients with newly diagnosed (ND) multiple myeloma (MM)
    Baz, R.
    Hussein, M. A.
    Sullivan, D.
    Raychaudhuri, J.
    Ochoa, L.
    Kosakowski, K.
    Nardelli, L.
    Dalton, W. S.
    Alsina, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion
    Berdeja, Jesus G.
    Gregory, Tara B.
    Faber, Edward
    Matous, Jeffrey
    Hart, Lowell
    Mace, Joseph R.
    Arrowsmith, Edward R.
    Flinn, Ian W.
    BLOOD, 2016, 128 (22)
  • [39] Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study
    Lonial, Sagar
    Baz, Rachid
    Bahlis, Nizar J.
    Chen, Christine I.
    Anderson, Kenneth C.
    Chen, Min
    Zaki, Mohamed
    Richardson, Paul G.
    BLOOD, 2012, 120 (21)
  • [40] Very Low to Low Doses of Continuous Azacitidine in Combination with Standard Doses of Lenalidomide and Low-Dose Dexamethasone (Rd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Interim Results of a Phase I/II Study
    Reu, Frederic J.
    Khan, Shahper N.
    Mahfouz, Reda Z.
    Dean, Robert M.
    Faiman, Beth
    Reed, Janice
    Karam, Mary Ann
    Hamilton, Kimberly
    Fada, Sherry
    Kalaycio, Matt
    Campagnaro, Erica L.
    Kindwall-Keller, Tamila L.
    Valent, Jason
    Samaras, Christy
    Sobecks, Ronald
    Jirousek, Carolyn
    Duong, Hien K.
    Orloff, Mohammed
    Saunthararajah, Yogen
    BLOOD, 2012, 120 (21)
12345